Kim J: Safety profile of poxviral vaccines: NCI Experience. Journal of Clinical Oncology 31:abstract 85, 2013 25. Sutter G, Staib C: Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3:263-71, 2003 26. Moorthy VS, McConkey S, Roberts M, et al: Safety of DNA and modified vaccinia virus Ankara vaccines against liver -stage P. falciparum malaria in non -immune volunteers. Vaccine 21:1995-2002, 2003 27. Amato RJ, Hawkins RE, Kaufman HL, et al: Vaccination of metastatic renal cancer patients with MVA -5T4: a randomized, double-blind, placebo- controlled phase III study. Clin Cancer Res 16:5539-47, 2010 28. Ramlau R, Quoix E, Rolski J, et al: A phase II study of Tg4010 (Mva- Muc1 -Il2) in association with chemotherapy in patients with stage III/IV Non -small cell lung ca ncer. J Thorac Oncol 3:735- 44, 2008 29. Scholl SM, Balloul JM, Le Goc G, et al: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23:570-80, 2000 30. Afonso CL, Tulman ER, Lu Z, et al: The genome of fowlpox virus. J Virol 74:3815-31, 2000 31. McLeod Dea : Phase I dose escalation trial of MVA -BN-PRO in men with nonmetastatic castration -resistant prostate cancer. .